The stock options have a optimum term of 7 years. Â Â Â.. Affymetrix acquires eBioscience Affymetrix Inc., today announced that the Company has completed its acquisition of eBioscience Keeping Company, Inc., a privately-held firm with an industry-leading placement in flow immunoassay and cytometry reagents for immunology and oncology analysis and diagnostics. The acquisition enhances Affymetrix’s product portfolio and expands its addressable marketplaces by more than $2.5 billion per year. Through the acquisition of eBio we’ve a blue-chip portfolio of cell-based assays that diversify our business and start important brand-new avenues for growth,’ said Dr. Frank Witney, president and chief executive officer of Affymetrix.PSM Solutions provide a mass customization of care strategy for participating providers to more effectively meet individuals where they are within their diabetes self-management trip. According to Benjamin M. Bluml, Senior Vice President of Research and Innovation for the Foundation, This answer enables pharmacists and other healthcare providers to get a comprehensive understanding of their patients’ ability to manage their diabetes through real life application of knowledge, performance and skills. Providers can customize and effectively direct treatment in patient populations then, resulting in better, less expensive outcomes for all patients and a proven cost benefits of over $1,000 per patient per year.